Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit ...Middle East

The SGLT2 inhibitor dapagliflozin was not associated with significant benefit in COVID-19 patients but came close in the DARE-19 trial. Medscape Medical News

Hence then, the article about dapagliflozin misses in covid 19 but intriguing signal of benefit was published today ( Tuesday 18/05/2021 - 08:31 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit )

Also on site :

• North Korea says its latest weapons tests included missiles with cluster-bomb warheads
• MLB Mailbag: Jordan Walker, Cubs, Guardians, Tigers, Riley
• Man rescued after two weeks trapped in collapsed Mexico mine